![Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7050e2_BoostersAdditionalPrimaryDoses_IMAGE_10Dec21_1200x627.jpg?_=35384)
Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR
![Cureus | A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants | Article Cureus | A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants | Article](https://assets.cureus.com/uploads/figure/file/451278/article_river_2ff8b2e0309d11eda32f8f6718c87cc5-covid-19-vaccine-normal.png)
Cureus | A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants | Article
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
![Frontiers | Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China Frontiers | Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China](https://www.frontiersin.org/files/Articles/834572/fpubh-10-834572-HTML/image_m/fpubh-10-834572-g001.jpg)
Frontiers | Association Between Risk Perception and Acceptance for a Booster Dose of COVID-19 Vaccine to Children Among Child Caregivers in China
![IJERPH | Free Full-Text | Behavioral Intention to Get a Booster Dose of COVID-19 Vaccine among Chinese Factory Workers IJERPH | Free Full-Text | Behavioral Intention to Get a Booster Dose of COVID-19 Vaccine among Chinese Factory Workers](https://pub.mdpi-res.com/ijerph/ijerph-19-05245/article_deploy/html/images/ijerph-19-05245-ag.png?1650956078)
IJERPH | Free Full-Text | Behavioral Intention to Get a Booster Dose of COVID-19 Vaccine among Chinese Factory Workers
![CDC on X: "The definition of fully vaccinated has not changed with expanded use of booster doses. You're considered fully vaccinated against #COVID19: - 2 weeks after your second dose of a CDC on X: "The definition of fully vaccinated has not changed with expanded use of booster doses. You're considered fully vaccinated against #COVID19: - 2 weeks after your second dose of a](https://pbs.twimg.com/media/FGGcBmmXoAE0gjg.jpg:large)
CDC on X: "The definition of fully vaccinated has not changed with expanded use of booster doses. You're considered fully vaccinated against #COVID19: - 2 weeks after your second dose of a
![MenACWY-CRM conjugate vaccine booster dose given 4–6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults - ScienceDirect MenACWY-CRM conjugate vaccine booster dose given 4–6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X19311417-gr1.jpg)
MenACWY-CRM conjugate vaccine booster dose given 4–6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults - ScienceDirect
![Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA](https://www.fda.gov/files/Booster%20Infographic_D_Rev_010622_0.png)
Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA
CDC - After FDA approves and ACIP recommends a COVID-19 booster dose, the goal is for those who received their shots in the earlier phases of vaccine rollout to get their booster
![Coronavirus (COVID-19) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine | FDA Coronavirus (COVID-19) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine | FDA](https://www.fda.gov/files/Booster%20Infographic_tw_12_28_21.png)
Coronavirus (COVID-19) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine | FDA
![Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/asset/3b4eb078-d7dd-4a37-98ea-553c444f2a49/gr1.jpg)